1389 related articles for article (PubMed ID: 22918931)
41. Macrophage-Mediated Subversion of Anti-Tumour Immunity.
Quaranta V; Schmid MC
Cells; 2019 Jul; 8(7):. PubMed ID: 31331034
[TBL] [Abstract][Full Text] [Related]
42. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
43. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
Abbott RC; Cross RS; Jenkins MR
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
[TBL] [Abstract][Full Text] [Related]
44. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
45. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
46. Adding fuel to the fire: immunogenic intensification.
O'Sullivan Coyne G; Gulley JL
Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
[TBL] [Abstract][Full Text] [Related]
47. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
48. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
49. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
[TBL] [Abstract][Full Text] [Related]
50. Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
Armitage JD; Newnes HV; McDonnell A; Bosco A; Waithman J
Cells; 2021 Jan; 10(1):. PubMed ID: 33401460
[TBL] [Abstract][Full Text] [Related]
51. Immune responses to malignancies.
Whiteside TL
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S272-83. PubMed ID: 20061007
[TBL] [Abstract][Full Text] [Related]
52. Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.
Karimi S; Chattopadhyay S; Chakraborty NG
Immunology; 2015 Feb; 144(2):186-96. PubMed ID: 25243729
[TBL] [Abstract][Full Text] [Related]
53. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
54. Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours.
Lowe KL; Cole D; Kenefeck R; OKelly I; Lepore M; Jakobsen BK
Cancer Treat Rev; 2019 Jul; 77():35-43. PubMed ID: 31207478
[TBL] [Abstract][Full Text] [Related]
55. Tumour-released exosomes and their implications in cancer immunity.
Iero M; Valenti R; Huber V; Filipazzi P; Parmiani G; Fais S; Rivoltini L
Cell Death Differ; 2008 Jan; 15(1):80-8. PubMed ID: 17932500
[TBL] [Abstract][Full Text] [Related]
56. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.
Carmi Y; Spitzer MH; Linde IL; Burt BM; Prestwood TR; Perlman N; Davidson MG; Kenkel JA; Segal E; Pusapati GV; Bhattacharya N; Engleman EG
Nature; 2015 May; 521(7550):99-104. PubMed ID: 25924063
[TBL] [Abstract][Full Text] [Related]
58. Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.
Jacqueline C; Finn OJ
Semin Immunol; 2020 Feb; 47():101394. PubMed ID: 32273212
[TBL] [Abstract][Full Text] [Related]
59. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
Li S; Bennett ZT; Sumer BD; Gao J
Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
[TBL] [Abstract][Full Text] [Related]
60. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
